Hurrell says ‘it’s the right choice’ to sell the co-op’s consumer business, which recorded the highest YoY operating profit ...

Taysha Gene Therapies' positive results from the REVEAL study showcase TSHA-102's promise in treating Rett Syndrome. Click ...

Bata India on Wednesday announced that the company’s consolidated net profit fell 27.8 per cent year-on-year (YoY) to Rs ...

The Birmingham-headquartered division has reported a pre-tax loss of £101.8m for 2024, having posted the same total for 2023 ...

Earnings growth is expected to "claw back" to around 12% to 13% in FY26. This will be backed by the "fairly positive" liquidity situation and improvement in the rural economy, according to Mahesh ...

Despite a Qualcomm job listing that hints otherwise, Microsoft's next-gen Xbox game consoles may not actually use ARM chips, ...

Built on a 22-nm process, Silicon Labs’ SiXG301 and SiXG302 wireless SoCs deliver improved compute performance and energy ...

but Arm’s key growth lever has shifted — from handset royalty volume to expanding exposure in data center and automotive silicon. In Q3, the company posted 14% year-over-year growth ...

In an exchange filing, the company stated that the USFDA has classified the inspection outcome as voluntary action indicated ...

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett ...

Shilpa Medicare jumped 7.88% to Rs 792.90 after its wholly owned subsidiary, Shilpa Biocare, entered into a strategic partnership with Orion Corporation to commercialise Recombinant Human Albumin in ...